Page last updated: 2024-12-05

glycyl-glycyl-glycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glycyl-glycyl-glycine (GGG) is a tripeptide composed of three glycine amino acid residues. It is a simple peptide that is often used as a model compound in studies of peptide structure and function. GGG is relatively easy to synthesize and has been studied for its potential applications in various fields, including medicine, biomaterials, and food science. GGG is found in various biological systems and can serve as a precursor for other peptides. It has been studied for its potential as a therapeutic agent, particularly in the treatment of cancer and Alzheimer's disease. GGG has also been shown to have antioxidant and anti-inflammatory properties, making it a potential candidate for use in cosmetics and other personal care products.'

glycyl-glycyl-glycine : A tripeptide in which three glycine units are linked via peptide bonds in a linear sequence. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID11161
CHEMBL ID54278
CHEBI ID63961
SCHEMBL ID98565
MeSH IDM0109114

Synonyms (55)

Synonym
triglycine ,
glycine, n-(n-glycylglycyl)-
n-(n-glycylglycyl)glycine
556-33-2
nsc46707
glycylglycylglycine
diglycylglycine
nsc-46707
glycylpeptide
gly-gly-gly
MAYBRIDGE1_006812
gly-gly-gly, bioultra, >=99.0% (nt)
bdbm50188484
[2-(2-amino-acetylamino)-acetylamino]-acetic acid
chebi:63961 ,
CHEMBL54278 ,
HMS560N14
2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetic acid
FT-0690006
h-gly-gly-gly-oh
G0126
glycyl-glycyl-glycine
AKOS005207234
einecs 209-122-0
unii-cvk73zdq8b
cvk73zdq8b ,
nsc 46707
glycine, glycylglycyl-
glyglygly
(gly)3
triglycine [usp-rs]
SCHEMBL98565
2-(2-(2-aminoacetamido)acetamido)acetic acid
(([(aminoacetyl)amino]acetyl)amino)acetic acid #
mfcd00036223
DTXSID80204140
glycylglycylglycine, 98+% (h-gly-gly-gly-oh)
triglycine (van)
glycine, n-(n-glycylglycyl)- (8ci)(9ci)
n-(n-glycylglycyl)-glycine
(([(aminoacetyl)amino]acetyl)amino)acetic acid
triglycine, united states pharmacopeia (usp) reference standard
SY025319
DS-7430
F17230
Q27132936
2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetic acid (triglycine)
glycylglycylglycine, triglycine
BP-31100
A848342
CS-W015952
2-[2-(2-aminoacetamido)acetamido]acetic acid
EN300-176110
2-({2-[(2-aminoacetyl)amino]acetyl}amino)acetic acid
HY-W015236
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
tripeptide zwitterionA peptide zwitterion obtained from the tranfer of a proton from the carboxy group to the amino group of any tripeptide. It contains an equal number of positively-charged and negatively-charged functional groups. Major structure at pH 7.3.
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)1,235.00000.18000.19000.2000AID266249; AID679007
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)1,070.00000.00020.660310.0000AID266249
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki160.00003.00006.47788.5000AID681124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID266249Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266246Activation of human PEPT1 expressed in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID681125TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID680830TP_TRANSPORTER: inhibition of VACV uptake (VACV: 0.2 uM, Gly-Gly-Gly: 10000 uM) in Xenopus laevis oocytes1998Biochemical and biophysical research communications, Sep-18, Volume: 250, Issue:2
Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID266248Ratio of %GSmax to EC50 for human PEPT1 activation2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID679007TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 25000 uM) in PEPT1-expressing CHO cells1996Pharmaceutical research, Nov, Volume: 13, Issue:11
Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells.
AID500816Inhibition of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID233320Bitter threshold value; NB denotes 'Not bitter'1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID681124TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID266247Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (91)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (9.89)18.7374
1990's12 (13.19)18.2507
2000's35 (38.46)29.6817
2010's30 (32.97)24.3611
2020's5 (5.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.51 (24.57)
Research Supply Index4.60 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.03%)5.53%
Reviews1 (1.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other95 (97.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]